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Purpose: Generic drugs use in the Liguria region is higher than the Italian average, but lower 
than in other European countries. No data exist about real-life prescription and level of aware-
ness of generic drugs. In this study, we analyzed demographic, social, economic and cultural 
factors that may affect the level of awareness of generic drugs and their effective use.
Methods: We conducted a population survey using a structured questionnaire, administered to 
a sample of 8 outpatient clinics of general practitioners located in different districts of Genoa 
(Liguria, Italy). Multivariate logistic modeling was adopted to study the relationship between 
awareness/use of generic drugs and characteristics of subjects.
Results: Out of 2,000 outpatients surveyed, 95% were aware of generic drugs: these were mostly 
females (OR =2.2, 95% CI: 1.4–3.6), .35 years old (OR .6.0 vs 18–35 years), with a high level 
of education (OR .4.4 vs “elementary sch”), living in the west side of the city (OR =1.9 vs 
center); of these, only 59% declared that they effectively use generic drugs. Users were younger 
(OR =3.1, 18–35 years vs .65 years), with a high level of education (high school/university 
degree vs no title/elementary/secondary school OR =1.7), and were aware of the lower cost 
compared with branded drugs, and were mainly informed by pharmacists and physicians.
Conclusions: Although subjects were substantially aware of the existence of generic 
drugs, ~40% still did not use them; doubts about their efficacy seem to be mainly driven by the 
idea that cheaper drugs lead to lower product quality, in terms of efficacy, safety and tolerability. 
New education policies on generic drugs are needed.
Keywords: generic drug, population-based survey, generic substitution, opinion, experience
Introduction
In many countries, generic substitution of an equivalent medicine (named also “generic 
drug”) for a branded medication has been in place for more than a decade: in some 
countries successfully (such as USA, Sweden, UK, the Netherlands and Germany), and 
in other countries such as Portugal, Spain, Greece and Italy, with a modest degree of 
acceptance.1 In particular, Italy has the lowest level of generic market share volume 
in Europe (,20%), immediately behind Portugal and Spain.1–6
In Europe, and especially in Northern European countries, the introduction of 
generic drugs (GDs) took place between the 1970s and 1980s. Italy is one of the 
European countries that has only recently clarified the concept of GD. The first com-
plete and comprehensive definition was introduced in 1996 with the law n. 425/1996. 
According to the Leg. Decree 219/2006 (implementing 2001/83/CE directive), the term 
GD refers either to drugs that have lost the patent (off-patent equivalent drugs), are 
characterized by a fancy name (branded generics), are “pure” generics identified by the 
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international non-proprietary name of the active ingredient 
followed by the name of the marketing authorization holder 
(unbranded generics), are a bioequivalent to a medicinal 
product already authorized with the same qualitative and 
quantitative composition of active ingredients, the same 
pharmaceutical form, and the same therapeutic indications. 
According to the laws 27/2012 and 135/2012, the physician is 
required to inform the patient of the existence on the market 
of a GD and to note only the name of the active ingredient 
in the National Health Service (NHS) prescription. Simoens 
et al have provided a comprehensive review on the current 
regulatory framework in Italy.7
Although the Italian policy of GDs promotion, by the phy-
sicians and pharmacists, is widespread, national data continue 
to highlight the limited success of GDs in Italy.4,6–9
Aims of the study
The purpose of this study is to investigate how the knowledge 
and use of GDs relate to socio-demographic variables and 
the approval rating of outpatients interviewed in Genoa, the 
regional capital of Liguria a Northern Italian region. Liguria 
was chosen for this study due to the fact that this Italian region 
appears to lag behind Northern Italy. National data on the per-
centage of GDs reimbursed by the NHS show that out of the 
total GD refunds, the Liguria region is slightly above (31.2%) 
the national average (28.4%; range 18.3%–44.3%).6,8,9
A secondary aim was to assess general practitioner 
prescriptions of GDs in the class of proton pump inhibitors 
(PPIs), which are widely used in Italy and are often taken 
outside the prescribing guidelines. In fact, according to the 
National Report of the Italian Medicines Agency (AIFA) on 
the use of drugs in the general population, PPIs rank among 
the top in terms of prescription and expenditure reimburse-
ment by the NHS.8,10
Methods
study population and design
This is a descriptive, cross-sectional population survey study. 
The study was authorized by the Ethics Committee of the 
Liguria region in Genoa. All subjects were invited to partici-
pate and the study was verbally explained. Informed consent 
of both patients and general practitioners (GPs) was acquired. 
Interviews with outpatients and GPs were carried out in total 
anonymity to protect personal privacy. The questionnaires 
were directly and verbally administered by a single physician 
interviewer/investigator with formal training in medicine, 
between March and October 2014.
The city of Genoa has about 585,000 inhabitants and 
525 GPs; 70% of GPs work in groups of 3–9, out of the same 
medical office. Every GP has a legal limit of 1,500 outpatients. 
For the purposes of our analysis, the city of Genoa was 
divided into 3 areas (east, west and center) with more or 
less equivalent numbers of inhabitants. These areas reflect 
the different socio-economic realities and demographic 
characteristics of citizens. The interviews took place at the 
8 headquarters of the main outpatient clinics of the individual 
surveyed areas of the city (Figure 1). The study was divided 
into 2 separate surveys. The first survey was conducted by 
administering a questionnaire to patients. Interviews were 
held in a private room of the clinic, during regular opening 
hours while patients were waiting for their appointment. 
Interviews were conducted both in the morning and after-
noon, to reduce differences in access across age and occupa-
tion classes. It is widely assumed that there is no difference 
between generic or equivalent, in-patent drug, off-patent 
drug, branded or unbranded GDs; therefore, we deliberately 
did not explain these differences to the population surveyed 
so as not to influence their opinions.
At the end of the interview, patients were allowed to ask 
for clarification on the survey or to express their views more 
freely to the same interviewer. As previously reported,11–13 
this method minimizes the bias due to differences in subjec-
tive interpretation during data collection.
With regard to the second survey, once the first survey 
was completed, a questionnaire was administered to the 
18 GPs, working in the same outpatient clinics as the previous 
survey in order to have a more complete picture of the use 
of GDs, assuming that GP preferences and medical advice 
influence patient use. This interview was also conducted in 
Figure 1 Maps, districts of genoa and headquarters of outpatient clinics involved 
in the survey.
Abbreviation: gPs, general practitioners.
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anonymity and privacy, and GPs participated voluntarily at 
the beginning or end of their shift. GPs were unaware of the 
results of the first survey.
Questionnaires
Two structured questionnaires were prepared: one for the 
patients and another for the GPs. Previous research results were 
taken into account when assembling the questionnaires.11,13,14 
All the questions were multiple choice and respondents could 
either choose an answer from between 5 and 8 options or 
simply answer in the affirmative or negative. The degree to 
which the patient questionnaire was comprehensible for par-
ticipants was tested in an initial pilot survey of 180 patients 
attending a single outpatient clinic; the questionnaire has 
not been validated.
The patient questionnaire (Figures S1 and S2) was 
addressed to subjects of both genders, aged above 18 years, 
stratified into 3 age categories (18–35, 36–64, $65), and 
according to their level of education and type of employment. 
The questionnaire consisted of 2 parts: the first part included 
4 statements to assess kinds of respondents (Figure S1, ques-
tions from 1/A to 4/A). The second part (Figure S2) included 
questions to assess patient knowledge (questions from 1/B to 
6/B) about generics and their use (questions 7/B and 8/B).
Respondents were asked if they had ever heard about 
GDs and, if yes, from whom (questions 1/B and 2/B); 
their approval rating and experience of drug substitution 
(question 4/B); if their physician had ever recommended 
the substitution of a branded medicine with a generic one 
thus saving money (question 3/B) or the possibility of sub-
stitution at the pharmacy (questions 6/B); the fifth question 
(question 5/B) was related to the assessment of their knowl-
edge of the non-substitutability of GD. Experience with 
generics, motives for use and reasons behind their choice to 
use or not to use generics were assessed through the questions 
7/B. Finally, the last question (8/B) assessed whether any 
side effects were observed when taking a GD.
For the second part of the study, a questionnaire 
(Figure S3) was administered by the researcher to GPs 
treating the same patients interviewed with the previous 
questionnaire. The structured questionnaire had 5 questions 
with a choice between at least 2 answers. Questions were 
related to the experiences, opinions and preferences in the 
area of PPIs prescription.
statistical methods
The descriptive statistics used were mainly absolute number 
and relative frequencies (%). Fisher exact (in case of 
2×2 comparisons or when expected numbers were ,10) or 
chi-square (2×n, with n.2) tests were adopted to test differ-
ences between subjects who were aware or unaware of GDs, 
and between users and non-users.
Multivariate logistic regression analysis was adopted 
to estimate and test (using the Wald test) the strength of 
the association in terms of odds ratio (OR) between GD 
awareness/use and all the main demographic and social 
characteristics.
All analyses were conducted using STATA (version 13, 
StataCorp., College Station, TX, USA) software and the 
graphs were obtained with R (version 3.2.0). Two-tailed 
probabilities were reported and a P-value of 0.05 was used 
to define nominal statistical significance.
Results
A total of 2,134 patients were asked to participate; of these, 
134 (6.2%, range 6%–18% for each of the involved districts) 
refused and 2,000 responded to the questionnaire.
respondents and knowledge of gD
Among the 2,000 patients interviewed, 1,896 (94.8%) 
declared that they were informed about the existence of 
the GDs. The main characteristics of responders in terms 
of knowledge of GDs are depicted in Table 1. Subjects 
informed about GDs were mostly females (61.1% compared 
with 45.2% among those uninformed), aged over 36 years 
old (93.6% vs 84.6%), with a high level of education (51.4% 
had a high school diploma or university degree vs 21.2%), 
and lived in the center-west side of the city (63.1% vs 51%). 
Office workers and professionals were significantly more rep-
resented among informed than uninformed subjects (23.8% 
vs 13.5%, respectively).
In the multivariate model (Figure 2), the factors that 
remain significantly associated with knowledge of GDs were 
being a female (OR =2.2; 95% CI: 1.4–3.6), age .36 years 
old (middle aged and over 64 years old, OR =7.0, 95% CI: 
3.4–14.8 and OR =6.0, 95% CI: 2.6–14.2, respectively, 
compared with the younger class), having an educational 
qualification higher than elementary school (secondary 
school OR =4.4, 95% CI: 2.6–7.6; high school diploma 
OR =11.2, 95% CI: 5.6–22.5; university degree OR =29.2, 
95% CI: 8.1–106.0), and residence in the western side of 
city (OR =1.9, 95% CI: 1.1–3.5).
Respondents and use of GD
Among interviewees who knew GDs, only 1,115 patients 
(58.8% of 1,896 patients who know GDs) declared that they 
use them. The main characteristics of GD users are depicted 
in Table 2.





Females were equally distributed between users and 
nonusers (60.3% vs 62.2%, respectively), while users were 
younger (#65 years old) than nonusers (54.0% vs 38.9%) 
and had a high level of education (57.2% had a high school 
diploma or university degree vs 42.9%). GD users were 
more informed by mass media (19.0% vs 15.1%) and more 
aware of the lower cost of GDs (79.4% compared with 70.8% 
among nonusers). Moreover, among nonusers, the majority 
had parents or friends who did not believe in their efficacy 
(68.6% compared with 44.8% in users). No differences in 
the areas of residence in Genoa were detected between users 
and nonusers.
In the logistic regression model (Figure 3), the factors 
significantly associated with use of GDs were younger 
age compared with over 65 years (18–35 years, OR =3.11, 
95% CI: 1.87–5.19; 35–64 years, OR =1.90, 1.43–2.52), a 
high level of education (high school diploma/university degree 
vs no title/elementary/secondary school OR =1.67, 95% CI: 
1.34–2.08), and the lower cost of GDs compared with brand-
name drugs (OR =1.59, 95% CI: 1.25–2.01); the only factor 
significantly associated with non-use of GDs was the mistrust 
of parents and friends (OR =0.34, 95% CI: 0.27–0.41).
Analysis of individual responses to questions 7 and 8, 
showed that the majority of users were confident about 
the equal effectiveness and quality of GDs compared with 
branded drugs; 38.3% of patients felt that GDs had the same 
efficacy as branded medicines; while 31.0% believed that 
they were less efficacious. Furthermore, 85.6% of them 
thought that GD use did not entail risks with respect to drug 
safety (Table 3).
Table 1 Main characteristics of subjects surveyed with respect to 
their knowledge of gDs, n=2,000
Variable(s) Knowledge of GDs P-value*
No Yes
N=104 N=1,896
n (%) n (%)
Gender 0.001
Male 57 (54.8) 738 (38.9)
Female 47 (45.2) 1,158 (61.1)
Age (years) ,0.001**
18–35 16 (15.4) 122 (6.4)
36–64 20 (19.2) 785 (41.4)
65+ 68 (65.4) 989 (52.2)
Education ,0.001**
elementary school 47 (45.2) 324 (17.1)
Middle school 27 (26.0) 576 (30.4)
high school diploma 19 (18.3) 731 (38.6)
University degree 3 (2.9) 242 (12.8)
no title 8 (7.7) 23 (1.2)
Occupation 0.04**
laborers 6 (5.8) 91 (4.8)
Office workers 11 (10.6) 312 (16.5)
Professionals 3 (2.9) 138 (7.3)
craftsman 1 (1.0) 13 (0.7)
students 4 (3.9) 20 (1.1)
Unemployed and retired 59 (56.7) 908 (47.9)
housewives 20 (19.2) 414 (21.8)
Side of Genoa 0.02**
east 51 (49.0) 699 (36.9)
center 26 (25.0) 474 (25.0)
West 27 (26.0) 723 (38.1)
Notes: Data are presented as absolute number (percentage); *Pearson’s chi-squared 
or Fisher exact test; **contrasts: age classes are all significantly different from each 
other; education: the only non-significant difference is between university degree 
and high school diploma; occupation: significant differences are between student 
and anyone of the others except craftsman, and between unemployed/retired and 
professionals; side of Genoa: the significant difference is between east and west.
Abbreviation: gDs, generic drugs.
Figure 2 Odds ratio adjusted for gender, age, education, job and genoa’s geographical area.
Abbreviation: gDs, generic drugs.
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All the 18 GPs surveyed answered the questionnaire. Due 
to the relatively low number of interviews carried out, the 
results cannot be statistically analyzed. Nonetheless, they 
showed that: 10 (55.6%) GPs preferred to prescribe lansopra-
zole, 7 (38.9%) used pantoprazole, and only 1 (5.6%) used 
omeprazole. Fifteen (83.3%) GPs stated that there was a jus-
tification for their preference, 2 (11.1%) GPs asserted that it 
was a habit and only 1 (5.6%) gave no particular reason. Ten 
(55.6%) GPs expressed a preference for the originator over 
the generic, 8 (44.4%) arbitrarily prescribed either branded 
or the GDs, and nobody specifically prescribed generics. 
All respondents (18/18) claimed to have found differences 
in the efficacy and/or tolerability of the GDs compared with 
the originator. Finally, the majority of respondents (13/18; 
72.2%) said that they discussed the differences in efficacy 
and tolerability between GDs and originators with colleagues 
and pharmacists (Table 4).
Discussion
The results of this survey showed that the degree of knowl-
edge of generics in the sample examined is almost optimal, 
although there is an imbalance between the genders.
In our sample, of the subjects informed about GDs the 
most were 1) females; 2) over 36 years old; 3) had a high 
level of education; 4) office/professional workers; 5) living 
in the center-west side (poorest areas) of the city.
Therefore, young patients with a modest education 
who lived on the east side (the richest district) of Genoa, 
represented the groups that should be addressed to increase 
awareness of GDs.
In our study, GD users amounted to 58.8% of those who 
knew the GDs; in the logistic regression model, the main 
factor significantly associated with use of GDs was a younger 
age compared with over 65, there is an inverse relationship 
between knowledge and use of GDs. Moreover, the main 
users of GDs were patients with a high level of education 
and were mostly informed by mass media, pharmacists and 
physicians.
In our opinion the knowledge of drugs being greater in 
the elderly than in the young is not surprising considering 
that patients .65 years have a higher risk of morbidity and 
co-morbidity and usually take more medicines than younger 
people. Young people contact their GP less frequently than 
elderly patients; therefore, they do not become aware of 
developments in treatments (ie, the existence of GDs) and 
they certainly do not have years of experience with branded 
drugs like elderly patients with chronic conditions requiring 
extended treatment. Young subjects usually only use a drug 
for an acute disease for a short period of time. Therefore, it 
Table 2 Main characteristics of subjects knowledgeable about 
gDs by use, n=1,896
Variable(s) Use of GDsa P-valueb
No Yes
N=781 N=1,115
n (%) n (%)
Gender 0.4
Male 295 (37.8) 443 (39.7)
Female 486 (62.2) 672 (60.3)
Age (years) ,0.001*
18–35 29 (3.7) 93 (8.3)
36–64 275 (35.2) 510 (45.7)
65+ 477 (61.1) 512 (45.9)
Education ,0.001*
elementary school 170 (21.8) 154 (13.8)
Middle school 268 (34.3) 308 (27.6)
high school diploma 240 (30.7) 491 (44.0)
University degree 95 (12.2) 147 (13.2)
no title 8 (1.0) 15 (1.3)
Occupation 0.002*
laborers 21 (2.7) 70 (6.3)
Office workers 115 (14.7) 197 (17.7)
Professionals 63 (8.1) 75 (6.7)
craftsman 6 (0.8) 7 (0.6)
students 5 (0.6) 15 (1.3)
Unemployed and retired 384 (49.2) 524 (47.0)
housewives 187 (23.9) 227 (20.3)
Area of Genoa 0.4
east 300 (38.4) 399 (35.8)
center 186 (23.8) 288 (25.8)
West 295 (37.8) 428 (38.4)
Source of information about GDs (Q.2/B) 0.003*
Doctors 239 (30.6) 333 (29.9)
Pharmacists 336 (43.0) 489 (43.9)
Mass media 118 (15.1) 212 (19.0)
People 27 (3.5) 36 (3.2)
Other 61 (7.8) 45 (4.0)
Knowledge about cheaper cost of GDs (Q.3/B) ,0.001
no 228 (29.2) 230 (20.6)
Yes 553 (70.8) 885 (79.4)
Mistrust of parents and friends (Q.4/B) ,0.001
no 245 (31.4) 615 (55.2)
Yes 536 (68.6) 500 (44.8)
Knowledge about the notion of non-substitutability 
(Q.5/B)
0.01
no 548 (70.2) 721 (64.7)
Yes 233 (29.8) 394 (35.3)
The pharmacist proposed the change to GDs 
(Q.6/B)
0.1
no 110 (14.1) 132 (11.8)
Yes 668 (85.5) 982 (88.1)
Notes: Data are presented as absolute number (percentage). anumber of users 
and nonusers was extrapolated from question Q.7/B, as the results of the sum of 
answers a–d (users), and the sum of the answers e–h (nonusers). bPearson’s chi-
squared or Fisher exact test. *Contrasts: age classes are all significantly different 
from each other; education: significant differences are between elementary 
school and high school/Univ. Degree and between middle and high school; 
occupation: significant differences are between laborers and any of the other 
occupations except for craftsman and students; source of info about gDs: the 
significant difference is between the category “other” and doctors/pharmacists/
mass media.
Abbreviation: gDs, generic drugs.





is reasonable to assume that in terms of percentage, young 
people are more inclined to use a GD only when it is pro-
posed by physicians/pharmacists or other sources of infor-
mation (mass media). Patients .65 years were less likely 
to accept substitution than younger patients. Increasing age 
is associated with a less favorable attitude toward GDs, and 
patients rarely agreed to use the GDs for the treatment of a 
serious illness.15
Similar considerations can be made for the degree of 
education; our data showed that knowledge and use of GDs 
were directly proportional to the degree of education, while 
other authors, such as Quintal et al,11 reported no significant 
differences in the use of GDs among levels of education but 
found a positive association with knowledge. This discrep-
ancy could be attributed to the sample interviewed and to 
the site where the interview was conducted; Quintal et al 
conducted the interviews in a chemist shops where a het-
erogeneous population was represented, whereas our study 
Figure 3 Odds ratio adjusted for gender, age, education, job, genoa’s geographical area, source of information about gDs, knowledge that gDs are cheaper brands, mistrust 
of parents and friends, knowledge of statement “not replaceable”, pharmacist proposal.
Abbreviation: gDs, generic drugs.
Table 3 Answer to questions #7, 8 (only to subjects knowledge-
able of generics, n=1,896)
Have you ever used GDs (Q.7/B) n (%)
Yes, with the same efficacy and I saved money at the  
same time
727 (38.3)
Yes, with less effects but i saved money 66 (3.5)
Yes, on recommendation by doctor/pharmacist 277 (14.6)
Yes, but i don’t know the real reason 45 (2.4)
Total of users 1,115 (58.8)
no, i’m afraid it has less therapeutic effect 587 (31.0)
no, i’m afraid of adverse effects 9 (0.5)
No, I am not sufficiently informed about generics 47 (2.5)
no, i don’t want to change 138 (7.3)
Total of nonusers 781 (41.2)
If you used GDs, did you experience any adverse 
effects or diseases? (Q.8/B)
n (%)*
Yes, so severe as to be hospitalized 7 (0.6)
Yes, i had to change therapy 84 (7.5)
Yes, i had to add other drugs to reduce adverse effects 61 (5.5)




Note: *Percentage is on 1,115 users.
Abbreviation: gDs, generic drugs.
Table 4 survey of PPi prescribing habits of general practitioners
N %




Is there a specific reason to prescribe a PPI? (Q2)
Yes, there is a reason 15 83.3
no, it is a habit 2 11.1
no particular reason 1 5.6
Prescription habits (Q3)
no difference 8 44.4
Prefer to prescribe branded medication 10 55.6
Prescribe generics 0 –
Difference in efficacy/tolerability compared with the  
branded (Q4)
Yes, sometimes 18 100
Discussion of differences with colleagues and pharmacists (Q5)
Yes 13 72.2
no 5 27.8
Abbreviation: PPis, proton pump inhibitors.
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was conducted in outpatient clinics with a selected patient 
population. In our case, young GD-users knew that GDs were 
cheaper than originators and they went to the physician to 
obtain a prescription of a drug paid by the NHS. The Italian 
NHS is peculiar because all patients receive most drugs 
without paying and this certainly also influences the choice 
to use a GD. In fact, the universal health coverage system 
on which the Italian NHS is based ensures that price differ-
ences between GDs and originators are modest. While this 
may interest a patient with a low income, it will not influence 
the choice of an elderly patient with a chronic illness who 
prefers to continue using the originator drug, whose efficacy 
and tolerability he knows, rather than make a potential saving, 
prevalently for the State, by choosing the GD.
In the study by Maly et al16 conducted in the Czech 
Republic, 74% of respondents believed in the full effect of 
GDs, while in another study conducted in Brazil,14 74.8% 
believed that GDs were as effective as the branded drugs; 
in a Finnish study, Heikkila et al13 reported that about 
80%–90% of respondents considered GDs and originators 
equally effective and thought that there were no differences 
in terms of quality, and only 16.3% of respondents rejected 
the replacement with an equivalent. Comparing these and our 
data, the results are quite different; the discrepancy between 
the studies could arise from the fact that the factor behind the 
decision to be a GD user is probably essentially a cultural 
factor in the sense that being aware of the existence of gener-
ics does not directly imply being well-informed about their 
efficacy and safety. There is scant scientific documentation 
on real-life clinical outcomes of substitution of treatment 
with GDs which has led to a sort of diffidence among Italian 
doctors and patients in relation to GD. Overall, our study’s 
data seem in line with that of the Nomisma report,17 which 
highlights an unbalanced framework in which Italian patients 
are knowledgeable about generics (90%) and 72% have used 
them in the last 12 months, but the market outcomes of GDs 
have not yet reached their full potential. There appears to be 
an “information vacuum” between doctors and GD produc-
ers, which leads to the use of “traditional” drugs, especially 
in cases of more serious illnesses. The main consequence of 
this is the need for more specific information about generics 
to be delivered correctly to all patients.
A positive result of our investigation is that 85.6% of 
GD users declared that they have experienced no more side 
effects than with branded drugs. However, 14.4% of patients 
who had used GDs declared that they had experienced 
more side effects than with branded drugs; this percentage 
is quite high and it is in clear contrast with the results of 
our second survey of the opinion of GPs on PPIs. In fact, 
all physicians surveyed still prefer to prescribe branded 
drugs instead of GDs, and they also declare that they have 
frequently found differences in efficacy and/or tolerability 
between GDs (generic PPIs) and originators. Although the 
limits of the second survey are obvious, and we are not able 
to give statistical meaning to the reported result, this seems 
to be an important sign of mistrust of GDs even among GPs 
themselves, which consequently affects their use by their 
own patients. These data appear in line with those of another 
study conducted in Saudi Arabia on physician opinions of 
GDs.18 This proves that a low level of knowledge among 
physicians about GDs might be a strong predictive factor 
for low prescription; therefore, increasing the knowledge 
among the GPs about the qualities and characteristics of 
GDs would lead to a promotion of their use. The European 
Generic and Biosimilar Medicines Association (EGA) study,5 
states that “physicians need to be exposed to a higher quality 
of information from the responsible authorities to improve 
the rational prescribing”, also through a strong intervention 
by governments. As reported by IMS Health study,2 in less 
developed GDs markets, such as Italy, the improvement of 
educational programs may be the best strategy to offer all the 
advantages of GDs rather than merely focus on price. Once 
again, Italian universal health coverage could be one of the 
reasons why GPs are no longer aware of GDs.
The main weakness of the present study is the lack of 
validation of the questionnaire. Moreover, it should be noted 
that this study was conducted in a single Italian city and it is 
important to underline that Liguria and, in particular, the city 
of Genoa, holds the highest Italian ageing index rate (ageing 
index in Liguria =239.5% vs Italian mean =151.4%; ISTAT 
data 201419); consequently, the largest number of respondents 
were over 65 years and only 6.4% patients were young. How-
ever, we believe in the importance of face-to-face interviews, 
rather than web-based or by telephone, with outpatients and 
their own physicians in order to provide new strategies to 
increase the knowledge/use of GDs. We think results from 
this study could be of interests to anyone who is interested in 
setting up a similar study, perhaps adopting validated tools 
and in a more extensive and comprehensive setting.
Conclusion
Despite a satisfactory knowledge of GDs in our region, data 
analysis shows that the degree of distrust is still very high and 
affects GD use; patients are still in doubt about GD efficacy. 
Unfortunately, the same degree of distrust is expressed by 
the GPs who are generally most concerned about potential 





changes in therapeutic effects, adverse effects and practical 
issues (eg, size, shape, and appearance) that may result from 
switching from branded to GDs. Patients should also be 
educated about the names of the active ingredients of their 
medicines to avoid confusion between different brands of 
the same medicine.
In the light of evidence on the advantages of GDs, both 
in money-saving terms and efficacy, promotion of these 
drugs is needed to assure both patients and GPs of their 
effectiveness and to combat the idea that cheaper products 
mean lower quality products, in terms of efficacy, safety 
and tolerability.
The previously formulated hypothesis, which associ-
ates scant use of GDs with the universal health coverage 
system, hampers appreciating the economic advantages of 
using GDs. Given that the low cost of GDs does not directly 
affect patients in Italy, in our opinion, information campaigns 
should be aimed at the economic advantages of GD use for 
the Italian state which, thanks to an increased use of GDs, 
would have more available economic resources to invest 
in innovative pharmaceuticals. An evident example of this 
are drugs for the treatment of the hepatitis C virus (HCV), 
which are only reimbursed to a limited number of patients 
selected on the basis of the seriousness of their hepatic ill-
ness. Thus, patients with low levels of liver impairment are 
excluded from reimbursement. Increased use of GDs would 
enable freeing up economic resources, which, in turn, could 
be used to extend the reimbursement of these drugs to all 
patients affected by HCV. We suggest directing an informa-
tion campaign centered on the economic advantages of GDs 
to the associations of patients that often complain about the 
disparity of access to innovative drugs (in this example, 
innovative drugs that treat HCV).
Finally, the limitations of our study notwithstanding, our 
results show that initial strategy to improve GDs knowledge 
should be targeted at young people, who require medical 
care less frequently and are therefore less informed by GPs 
or pharmacists.
It is more difficult to find an appropriate strategy for 
subjects with a low level of education or patients with higher 
economic status who have less need of GDs. Since results 
show that knowledge is directly proportional to the degree 
of education, an effective strategy should take advantage of 
the mass media as sources of information that rarely deal 
with this topic.
The trust of Italian patients in GDs is growing,17 but 
further improvement of information sources would allow 
younger patients to establish a trusting relationship with 
physicians. Health care professionals have an important role 
to play in helping patients understand that GDs are as safe 
and effective as originators. GDs manufacturers and dis-
tributors should work to fill this dearth of information by devel-
oping studies and exchanging information with physicians.
Key points
•	 Degree of distrust of GDs is very high and affects their 
use
•	 Women have twice the probability of having knowledge 
of a GDs compared with men
•	 Level of education is positively associated with knowl-
edge of GD
•	 The main reason for using GDs instead of branded ones 
is the cost-effectiveness
•	 Subjects informed about GDs by the GPs have a higher 
probability of using them.
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Part A – Questions regarding the patient interviewed
Q.1/A Gender: A. Male B. Female













F. Unemployed, underemployed, retired
G.	 Housewife
Figure S1 Questionnaire 1: Questionnaire survey of generic drugs use.
Part B – Questions regarding the survey about equivalents/generic drugs
Q.1/B Have you ever heard about generic drugs?
 A. Yes B. No
If no, the survey ends here.
If yes, go to question 2/B.
Q.2/B	From	whom	did	you	hear	about	generic	drugs?
A. General practitioner or other specialist;
B. Pharmacist;
C.	 Mass	media	(TV,	radio,	web,	newspapers);
D. Relatives, colleagues, friends, acquaintances;
E. Other
Q.3/B When your family doctor prescribes a drug, does he inform you that you can choose generic drug/equivalent drugs in lieu of 
brand-name drugs, thus saving money?
 A. Yes B. No
Q.4/B	Among	your	friends,	relatives	and	acquaintances,	have	you	noticed	any	skepticism	or	distrust	vis-à-vis generic drugs?
 A. Yes B. No
Q.5/B	Did	you	know	that	your	doctor	can	write	“do	not	replace”	on	a	prescription	if	he	considers	the	assumption	of	that	brand-name	
drug, rather than a generic one, important?
 A. Yes B. No
Q.6/B	Has	your	pharmacist	ever	proposed	substituting	a	brand-name	drug	with	another	equivalent/generic	drug?
 A. Yes B. No
Q.7/B Have you ever used equivalent/generic drug drugs?
A. Yes,	because	I	think	that	the	generic	drugs	have	the	same	therapeutic	effects	of	the	original	drug	and	I	save	money	
B. Yes, because I save money, so I accept the lesser therapeutic effects
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generic drugs: opinions and satisfaction of outpatients
Figure S2 Questionnaire 1: Questionnaire survey of generic drugs use.
G. no,	I’m	not	very	knowledgeable	about	this	topic	and	therefore	I	would	need	more	reassurance	and/or	explanations	before	trying	
an equivalent instead of the original brand-name drug
H. no,	I	am	not	very	knowledgeable	about	this	topic,	and	even	if	I	were,	I	would	not	substitute	the	original	drug
Answer the next question only if you have used generic drugs:
Q.8/B	Have	you	ever	had	side	effects	or	disorders	when	using	generic/equivalent	drugs	instead	of	the	original?




D. Yes, but I did not tell my doctor or anyone else 
E. No
Q1 – Tick the active substance of the PPI class that you usually prefer to prescribe:
Omeprazole	();	lansoprazole	();	pantoprazole	();	esomeprazole	();	rabeprazole	();	I	have	no	particular	preferences,	and	agree	to	any	
specific	patient	requests	().
Q2 – If you have a preference in prescribing a PPI, is there a specific reason or is it based on your habits?
Yes,	there	is	a	reason	();	No	there	is	no	particular	reason,	it’s	a	habit	().
Q3 – Do you prescribe medication without specifying the “no substitution” or do you think that it is unimportant whether 




Q4 – When you prescribed generic PPIs, or when a patient received a generic PPI from the pharmacist, have you ever found 
any difference in efficacy or tolerability compared to brand-name drugs?
No,	never	();	Yes,	sometimes	();	Only	with	a	particular	type	of	generic	medication	().
Q5 – If you found differences in efficacy and tolerability in a generic drug compared with the original medicine, did you report 
it or talk about it with colleagues or pharmacists?
Yes	();	No	().
Figure S3 Questionnaire 2: survey of PPi prescribing habits of general practitioners.
